文献速递胃肠外科

循环肿瘤DNA评估预测局部晚期食管鳞癌术后复发风险

Circulating Tumor DNA Assessment to Predict Risk of Recurrence After Surgery in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study.
PubMed 文献 · Ann Surg · 2025-03-21

这项前瞻性观察研究纳入28例接受新辅助化疗后手术的局部晚期食管鳞癌患者,用个体化肿瘤信息16-plex mPCR-NGS法在多时间点检测ctDNA。结果显示术后MRD窗口ctDNA阳性者复发率100%、阴性者30.4%,RFS显著更差(HR 30.99,P<0.0001)。

要点

  • 新辅助化疗后术前ctDNA阳性者复发率77.8%,阴性者27.8%,RFS更差(HR 4.56,P=0.01)。
  • 术后2-16周MRD窗口ctDNA阳性者复发率100%,阴性者30.4%,RFS显著更差(HR 30.99,P<0.0001)。
  • 术后>16周随访期可检出ctDNA与不良RFS显著相关(HR 27.34,P=0.003)。

核心结论

  • 基于ctDNA的MRD评估可能对评价食管鳞癌患者有价值,尤其在新辅助化疗后和术后场景。

研究设计与样本

  • 前瞻性纳入计划接受新辅助化疗后手术的局部晚期食管鳞癌患者。
  • 本报告回顾性分析28例接受根治性手术且肿瘤组织全外显子测序成功的患者。
  • 采用个体化肿瘤信息16-plex mPCR-NGS法在新辅助化疗前、新辅助化疗后术前、术后及随访纵向多时间点检测ctDNA。

主要发现

  • 新辅助化疗前ctDNA检出率:I期50%,II、III、IV期100%。
  • 新辅助化疗后术前ctDNA检出率33.3%。
  • ctDNA阳性者复发率77.8%,阴性者27.8%,RFS显著更差(HR 4.56,P=0.01)。
  • 术后MRD窗口(2-16周)ctDNA阳性者复发率100%,阴性者30.4%,RFS显著更差(HR 30.99,P<0.0001)。
  • 术后随访期(>16周)可检出ctDNA与不良RFS显著相关(HR 27.34,P=0.003)。

临床怎么用

  • 可考虑在新辅助化疗后术前及术后MRD窗口检测ctDNA,辅助识别食管鳞癌高复发风险患者。

局限性

  • 本报告仅纳入28例接受根治性手术且全外显子测序成功的患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between perioperative ctDNA status and prognosis in patients with esophageal squamous cell carcinoma (ESCC). BACKGROUND: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for assessing molecular residual disease (MRD) in various malignancies. However, there are limited studies evaluating the utility of ctDNA for predicting recurrence risk in patients with ESCC. METHODS: We prospectively enrolled patients with locally advanced ESCC who were scheduled to receive neoadjuvant chemotherapy (NAC) followed by surgery. This report retrospectively analyzed ctDNA with a personalized, tumor-informed 16-plex mPCR-NGS assay at multiple time points: pre-NAC, post-NAC but before surgery, postoperatively, and longitudinally during follow-up. RESULTS: A total of 28 patients who underwent curative surgery and had successful whole-exome sequencing analyses of tumor tissue samples were included in this report. At the pre-NAC time point, ctDNA was detected in 50% of patients with stage I and 100% of those with stages II, III, and IV. Post-NAC but before surgery, ctDNA was detected in 33.3% of patients. The recurrence rate was 77.8% in ctDNA-positive patients compared to 27.8% in ctDNA-negative patients, with significantly worse recurrence-free survival (RFS) for ctDNA-positive patients vs. ctDNA-negative patients (HR: 4.56, P =0.01). In patients analyzed during the MRD window (2-16 weeks post-surgery), the recurrence rate was 100% in ctDNA-positive patients compared with 30.4% in ctDNA-negative patients, with significantly worse RFS (HR: 30.99, P <0.0001). Similarly, during surveillance (>16 weeks postsurgery), detectable ctDNA was significantly associated with poor RFS (HR: 27.34, P =0.003). CONCLUSIONS: This study suggests that ctDNA-based MRD assessment may be valuable for evaluating patients with ESCC, particularly in post-NAC and postsurgical settings.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Takei S, Kotani D, Laliotis G, et al. Circulating Tumor DNA Assessment to Predict Risk of Recurrence After Surgery in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study. Ann Surg. 2025. PMID: 40115982. doi:10.1097/SLA.0000000000006699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。